ZRANB2 Human Pre-designed siRNA Set A contains three designed siRNAs for ZRANB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZRANB3 Human Pre-designed siRNA Set A contains three designed siRNAs for ZRANB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZRSR2 Human Pre-designed siRNA Set A contains three designed siRNAs for ZRSR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN10 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN12 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN2 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN21 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN21 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN25 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN25 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSCAN4 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSCAN4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSWIM4 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSWIM4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSWIM5 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSWIM5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSWIM6 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSWIM6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZSWIM8 Human Pre-designed siRNA Set A contains three designed siRNAs for ZSWIM8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZUP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ZUP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZW10 Human Pre-designed siRNA Set A contains three designed siRNAs for ZW10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZWILCH Human Pre-designed siRNA Set A contains three designed siRNAs for ZWILCH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZWINT Human Pre-designed siRNA Set A contains three designed siRNAs for ZWINT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZX703 (compound 5I) is a PROTAC that significantly degrades GPX4 in a dose- and time-dependent manner through the ubiquitin-proteasome and autophagy-lysosome pathways (DC50=0.315 µM). ZX703 induces ferroptosis by inducing Reactive Oxygen Species (ROS) accumulation in cells. ZX703 can be used for cancer research[1].

ZXDA Human Pre-designed siRNA Set A contains three designed siRNAs for ZXDA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZXDB Human Pre-designed siRNA Set A contains three designed siRNAs for ZXDB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZXDC Human Pre-designed siRNA Set A contains three designed siRNAs for ZXDC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZYG11B Human Pre-designed siRNA Set A contains three designed siRNAs for ZYG11B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Zymolyase, Arthrobacter luteus, is a zymolyase mainly found in Arthrobacter luteus. Enzyme, an enzyme with beta-1,3 glucanase activity, removes the electron-dense outer layer of the Plasmodium karinii cell wall, exposing an electron-lucent layer[1].

ZYX Human Pre-designed siRNA Set A contains three designed siRNAs for ZYX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZZEF1 Human Pre-designed siRNA Set A contains three designed siRNAs for ZZEF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ZZZ3 Human Pre-designed siRNA Set A contains three designed siRNAs for ZZZ3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a […]

α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC50 = 30.39 μM) and α-glucosidase (IC50 = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier[1].

α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research.[11][1].

α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of α-Amylase/α-Glucosidase that can be used for diabetes research[1].

α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes[1].

α-Cadinol is an antifungal agent that can inhibit the growth of Coriolus versicolor and Laetiporus sulfureus.α-Cadinol also possesses antimite activity[1].

α-CN-TO is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely […]

α-Glucosidase-IN-48 (compound 9) is a potent inhibitor of α-Glucosidase, with IC50 of 1.30 μM[1].

α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice[1].

α-Glucosidase-IN-50 (compound 8) is an inhibitor of α-Glucosidase[1].

α-Glucosidase-IN-51 (compound 9) is an inhibitor of α-Glucosidase[1].

α-Glucosidase-IN-52 (Compound 3h) is an α-glucosidase inhibitor with an IC50 of 2.8 μM. α-Glucosidase-IN-52 can be used for diabetes research[1].

α-Glucosidase-IN-54 (compound 2) is a α-glucosidase inhibitor with the IC50 of 0.011 mM, and can be isolated form Syzygium jambos (L.). α-Glucosidase-IN-54 can be used for study of diabetes[1].

α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health[1].

α-Glucosidase-IN-56 (compound 1) is an orally active, potent α‐glucosidase inhibitor with an IC50 value of 45.86 μM. α-Glucosidase-IN-56 has potent anti-glycation activities[1].

α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research[1].

α-Glucosidase-IN-58 (Compound 6d) is an inhibitor for α-glucosidase with IC50 of 1.47 μM[1].

α-Glucosidase-IN-59 (Compound 5b) is an inhibitor for α-glucosidase with IC50 of 1.16 μM[1].

α-Glucosidase-IN-60 (Compound 5k) exhibits a competitive inhibitory efficacy against α-Glucosidase, with IC50 of 10.8 μM[1].

α-Glucosidase-IN-61 (Compd 1j), a competitive α-glucosidase inhibitor, demonstrates excellent inhibition with an IC50 of 0.73 μM. α-Glucosidase-IN-61 (Compd 1j) is used for the research of type 2 diabetes mellitus[1].

α-Hexylcinnamaldehyde-d5 is deuterated labeled Diacetoxyscirpenol (HY-N6692). Diacetoxyscirpenol (DAS) is a trichothecene mycotoxin, a secondary metabolite product of fungi. Diacetoxyscirpenol (DAS) consumption induces haematological disorders (neutropenia, aplastic anemia) in human and animals[1].

α-Isopropylmalate (Standard) is the analytical standard of α-Isopropylmalate. This product is intended for research and analytical applications. α-Isopropylmalate (α-IPM) is the leucine biosynthetic precursor in Yeast[1].

α-Lactalbumin is a Ca2+-binding protein. α-Lactalbumin has a single strong Ca2+-binding site and for this reason it frequently serves as a simple model Ca2+-binding protein. α-Lactalbumin is a component of lactose synthase, an enzyme system, which consists of galactosyltransferase (GT) and α-Lactalbumin[1][2].